CDKN2AIPNL: A Promising Drug Target and Biomarker for Cancer (G91368)

Target Name: CDKN2AIPNL

NCBI ID: G91368

CDKN2AIPNL: A Promising Drug Target and Biomarker for Cancer

Introduction

CDKN2AIPNL, a gene named after its encoded protein, is a non-coding RNA molecule that plays a critical role in regulating various cellular processes. CDKN2AIPNL has been identified as a potential drug target and biomarker for cancer, due to its unique structure, expressed levels , and involvement in multiple cellular pathways. In this article, we will explore the CDKN2AIPNL molecule, its potential as a drug target, and its involvement in cancer biology.

Structure and Expression

CDKN2AIPNL is a small non-coding RNA molecule that contains 23 amino acid residues. It is expressed in various tissues and organs, including brain, heart, liver, and pancreas. The molecule has a unique structure, with a conserved N-terminus and a unique C-terminus that contains a farnesylated cysteine 鈥嬧?媟esidue.

CDKN2AIPNL functions as a negative regulator of the tumor suppressor gene p53. It binds to the p53 protein and inhibits its DNA-binding activity, thereby leading to the suppression of gene expression and cell proliferation. CDKN2AIPNL has been shown to play a crucial role in the regulation of cell cycle progression, apoptosis, and metabolism.

CDKN2AIPNL and Cancer

CDKN2AIPNL's involvement in cancer biology is multifaceted and complex. It has been shown to be involved in the regulation of apoptosis, a critical mechanism that regulates cell death and is critical for cancer prevention. In addition, CDKN2AIPNL has been shown to play a role in the regulation of cell cycle progression, which is a critical factor in the development and progression of cancer.

CDKN2AIPNL has also been shown to be involved in the regulation of angiogenesis, a process that is critical for the development of new blood vessels that feed into tumors. The lack of proper angiogenesis can be a therapeutic approach for cancer treatment.

CDKN2AIPNL as a Drug Target

CDKN2AIPNL's unique structure and function make it an attractive drug target. Drugs that target CDKN2AIPNL have been shown to have various therapeutic effects, including inhibition of cancer cell proliferation, delayed cell cycle progression, and enhanced apoptosis.

One of the most promising CDKN2AIPNL drug targets is the inhibition of its interaction with the p53 protein. The p53 protein is a well-established cancer drug target that has been shown to play a critical role in the regulation of apoptosis. By inhibiting the interaction between CDKN2AIPNL and p53, drugs can enhance the inhibition of apoptosis and potentially lead to the reversal of its effects.

Another potential CDKN2AIPNL drug target is its role in the regulation of cell cycle progression. CDKN2AIPNL has been shown to play a role in regulating the length of the cell cycle, which can be a therapeutic approach for cancer treatment. By inhibiting CDKN2AIPNL's function in regulating cell cycle progression, drugs can disrupt the regulation of apoptosis and potentially lead to the reversal of its effects.

CDKN2AIPNL as a Biomarker

CDKN2AIPNL has also been shown to be an attractive biomarker for cancer. Its unique expression levels and its involvement in various cellular pathways make it a potential biomarker for cancer diagnosis and treatment.

CDKN2AIPNL has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Its expression levels are also known to be associated with cancer outcomes, such as poor prognosis and survival. In addition , its unique structure and function make it a potential biomarker for cancer diagnosis and treatment.

Conclusion

CDKN2AIPNL is a non-coding RNA molecule that plays a critical role in

Protein Name: CDKN2A Interacting Protein N-terminal Like

More Common Targets